{'en': 'Dexcom G6 - will arrive in Spain in the second half of the year', 'es': 'Dexcom G6 - Llegará a España en el segundo semestre del año'} Image

Dexcom G6 - will arrive in Spain in the second half of the year

fer's profile photo   06/06/2018 5:26 p.m.

The new Dexcom firm's device to treat diabetes, called “G6”, will arrive in Spain in the second semester of this year.

The Gadget presents many novelties with respect to the previous edition, improving the detection of blood glucose levels of patients with this pathology (from two years of age).Its main differentiating characteristic is that to calibrate the system no drop of blood is needed.

Last March, the FDA allowed its commercialization in the United States and became the first continuous glucose monitoring system, allowed by this institution, which is integrated with other compatible medical devices, such as with insulin dosing or other types or other typesof technology used for diabetes control.This authorization also submits the product to some "special" criteria, so that the market will be cheaper.

The Dexcom G6 is an element that is incorporated into the skin of the abdomen, as well as its previous versions, and that through a small sensor measures the amount of glucose of the body fluid.In this way, the device transmits real -time glucose levels every five minutes to any external platform, both apps on the mobile phone and smart watches.This variety of compatible applications provides the patient with more flexibility and comfort at the time of use.In addition, it allows sharing the data collected with up to five people.

In this sense, it integrates an automatic insulin dosage system that acts accordingly to blood sugar levels.The device should be replaced every 10 days and, as a novelty, the G6 is factory calibrated and does not need patients to do it with a puncture and a drop of blood.

Dexcom allies with Verily (Alphabet) to improve the G6

The main novelty is that the G6 will be the basis in which portable technology that "revolutionize" the treatment for diabetics by Dexcom and Verily Life Sciences, subsidiary of Alphabet (Google) will be built, by an agreement reached recently reachedMore than a month, as published by the Wareable Platform.

This alliance with Verily could favor Dexcom in the coming years, thanks to access to a very specific technology and his "knowing how to do" in miniaturization sensors.It is not yet known when you can see the first wearable created by both companies but it is known that it will be even smaller than the G6 and that it could be disposable while very economical.

Attention to Verily ... here several issues related to the company:

Link
Link
Link

fer's profile photo
fer
06/06/2018 5:26 p.m.

@fer - Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro.
Co-Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.

  

Let's see if it is true that in the not too distant future it is smaller and more economical.

Maritxu22's profile photo
Maritxu22
06/07/2018 9:27 p.m.

DM1 desde abril 2006. 33años
Tresiba:12-14
Fiasp a demanda
Dexcom G6

Última HbA1c: 6% (junio)

  

Join the Discussion!

To participate in this thread, please register or log in.